These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24622699)

  • 1. Pancreatitis and incretin-based drugs: clarity or confusion?
    Nauck MA; Meier JJ
    Lancet Diabetes Endocrinol; 2014 Feb; 2(2):92-3. PubMed ID: 24622699
    [No Abstract]   [Full Text] [Related]  

  • 2. The safety of incretin based drugs.
    Montori VM
    BMJ; 2014 Apr; 348():g2779. PubMed ID: 24764568
    [No Abstract]   [Full Text] [Related]  

  • 3. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

  • 4. ACP Journal Club. Incretin use was not associated with increased risk for acute pancreatitis.
    Schectman J
    Ann Intern Med; 2015 Jun; 162(12):JC12. PubMed ID: 26075777
    [No Abstract]   [Full Text] [Related]  

  • 5. Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
    Smits MM; Muskiet MH; Tonneijck L; van Raalte DH
    Diabetes Care; 2015 Jul; 38(7):e106-7. PubMed ID: 26106231
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
    Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
    Diabetes Care; 2015 Jul; 38(7):e108-9. PubMed ID: 26106232
    [No Abstract]   [Full Text] [Related]  

  • 7. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
    Roshanov PS; Dennis BB
    Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
    Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
    N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
    [No Abstract]   [Full Text] [Related]  

  • 9. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study.
    Giorda CB; Picariello R; Nada E; Tartaglino B; Marafetti L; Costa G; Gnavi R
    Lancet Diabetes Endocrinol; 2014 Feb; 2(2):111-5. PubMed ID: 24622714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
    Jermendy G
    Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
    Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
    Diabetes Care; 2015 Jun; 38(6):1089-98. PubMed ID: 25633664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
    Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
    Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
    Moses A
    BMJ; 2013 Jul; 347():f4386. PubMed ID: 23842435
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation.
    Kmietowicz Z
    BMJ; 2013 Jun; 346():f3782. PubMed ID: 23757752
    [No Abstract]   [Full Text] [Related]  

  • 15. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
    Nauck MA; Meier JJ; Schmidt WE
    Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
    [No Abstract]   [Full Text] [Related]  

  • 16. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
    Faillie JL; Azoulay L; Patenaude V; Hillaire-Buys D; Suissa S
    BMJ; 2014 Apr; 348():g2780. PubMed ID: 24764569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preying on the pancreas? Scientists debate whether newer diabetes medications do harm.
    Berg EG
    Diabetes Forecast; 2013 Oct; 66(10):26, 28, 30-1. PubMed ID: 24224353
    [No Abstract]   [Full Text] [Related]  

  • 18. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position.
    Giorda CB; Nada E; Tartaglino B; Marafetti L; Gnavi R
    Diabetes Obes Metab; 2014 Nov; 16(11):1041-7. PubMed ID: 24702687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know.
    Forsmark CE
    Pancreatology; 2016; 16(1):10-3. PubMed ID: 26795258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.
    Azoulay L
    Diabetes Care; 2015 Jun; 38(6):951-3. PubMed ID: 25998285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.